Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Leor Roseman, Eline Haijen, Kelvin Idialu-Ikato, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1076-1087
Closed Access | Times Cited: 290

Showing 1-25 of 290 citing articles:

Trial of Psilocybin versus Escitalopram for Depression
Robin Carhart‐Harris, Bruna Giribaldi, Rosalind Watts, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 15, pp. 1402-1411
Open Access | Times Cited: 987
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Franz X. Vollenweider, Katrin H. Preller
Nature reviews. Neuroscience (2020) Vol. 21, Iss. 11, pp. 611-624
Closed Access | Times Cited: 406
Increased global integration in the brain after psilocybin therapy for depression
Richard E. Daws, Christopher Timmermann, Bruna Giribaldi, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 844-851
Open Access | Times Cited: 303
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
Gabrielle Agin-Liebes, Tara C. Malone, Matthew M. Yalch, et al.
Journal of Psychopharmacology (2020) Vol. 34, Iss. 2, pp. 155-166
Closed Access | Times Cited: 262
Long-term effects of psychedelic drugs: A systematic review
Jacob S. Aday, Cayla M. Mitzkovitz, Emily K. Bloesch, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 113, pp. 179-189
Closed Access | Times Cited: 183
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Erwin Krediet, Tijmen Bostoen, Joost J. Breeksema, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 23, Iss. 6, pp. 385-400
Open Access | Times Cited: 181
Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects
Jacob S. Aday, Alan K. Davis, Cayla M. Mitzkovitz, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 424-435
Open Access | Times Cited: 167
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 925-946
Open Access | Times Cited: 166
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 161
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
Kwonmok Ko, Gemma Knight, James Rucker, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 153
Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness
Hannes Kettner, Fernando E. Rosas, Christopher Timmermann, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 143
Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression
Roberta Murphy, Hannes Kettner, Rick Zeifman, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 140
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Max Wolff, Ricarda Evens, Lea J. Mertens, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 139
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD
Alan K. Davis, Frederick S. Barrett, Sara So, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 437-446
Open Access | Times Cited: 129
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Joost J. Breeksema, Bouwe Kuin, Jeanine Kamphuis, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 10, pp. 1100-1117
Open Access | Times Cited: 126
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Michiel van Elk, David B. Yaden
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104793-104793
Open Access | Times Cited: 106
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
Joseph Peill, Katie Trinci, Hannes Kettner, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 31-45
Open Access | Times Cited: 102
Must Psilocybin Always “Assist Psychotherapy”?
Guy M. Goodwin, Ekaterina Malievskaia, Gregory A. Fonzo, et al.
American Journal of Psychiatry (2023) Vol. 181, Iss. 1, pp. 20-25
Closed Access | Times Cited: 95
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world
Rosalind Watts, Hannes Kettner, Dana Geerts, et al.
Psychopharmacology (2022) Vol. 239, Iss. 11, pp. 3461-3483
Open Access | Times Cited: 83
Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses
Drummond E-Wen McCulloch, Gitte M. Knudsen, Frederick S. Barrett, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 138, pp. 104689-104689
Open Access | Times Cited: 76
Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations
Christopher Timmermann, Rosalind Watts, David Dupuis
Transcultural Psychiatry (2022) Vol. 59, Iss. 5, pp. 691-704
Open Access | Times Cited: 75
Case analysis of long-term negative psychological responses to psychedelics
Rebecka Bremler, Nancy Katati, Parvinder Shergill, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 42
Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 18
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects
Helena D. Aicher, Michael J. Mueller, Dario A. Dornbierer, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 16
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top